33-505 : Special Drug Use-Results Survey of OPDIVO

33-505 : Special Drug Use-Results Survey of OPDIVO (Pediatric Patients with Recurrent or Refractory Classical Hodgkin Lymphoma)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031240473

Enrollment

Registered

2024-11-08

Start date

2021-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent or Refractory Classical Hodgkin Lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pediatric patients with recurrent or refractory classical hodgkin lymphoma, who have recieved OPDIVO for the first time

Exclusion criteria

Exclusion criteria: 'Patients who have received OPDIVO previously

Design outcomes

Primary

Measure	Time frame
'[Safety] a) Occurrence status of adverse drug reactions and infections b) Adverse events	—

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-6-6222-5501

Outcome results